secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-07-18T23:59:59+00:00
Accession:  0001140361-23-034885
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics issues $8.715M in 6% convertible notes and warrants
-----------------------------------------------------------------------

- Aggregate principal $8,715,000, 6.0% Senior Convertible Notes due July 14, 2028; interest payable quarterly.
- Warrants to purchase up to 6,094,392 shares at $2.61/share (200% of conversion shares); exercisable for 5 years.
- Initial conversion price $2.86/share; notes subject to beneficial ownership conversion limitations (4.99%-19.99%).
- Directors Brant Binder and Richard Wagner, and former directors, participated on same terms as other purchasers.
- Net proceeds for general working capital; Registration Rights Agreement to be filed within 30 days of closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123034885/0001140361-23-034885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123034885/brhc20055909_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-034885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer